LYSORYNX, lozenge tablet sweetened with sorbitol and with saccharin 36 tablets
Active ingredients: Lysozyme hydrochloride, Cetylpyridinium chloride
Commercialized according to BDPM
Lozenge tablet36 tabletsvoie buccale autre
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LYSORYNX, comprimé à sucer édulcoré au sorbitol et à la saccharine
- Pharmaceutical form
- comprimé à sucer
- Route of administration
- voie buccale autre
- Presentation description
- 2 tube(s) polypropylène de 18 comprimé(s)
- Marketing authorisation holder
- LABORATOIRE CHAUVIN
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 21 Nov 2022
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68888543CIP73012633CIP133400930126332Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORURE DE CÉTYLPYRIDINIUMcomprimé | 1,5 mg · un comprimé | SA |
| CHLORHYDRATE DE LYSOZYMEcomprimé | 20 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.